Butterfly Medical awarded CE Mark for prostate device

Butterfly Medical awarded CE Mark for prostate device

Israeli medical device company Butterfly Medical today announced that its novel medical device for non-surgical, office-based treatment of Benign Prostate Hyperplasia (BPH), has obtained European CE Mark approval.

Butterfly Medical’s solution expands the treatment options for BPH sufferers, by providing a simple, fast and minimally invasive, in-office procedure, as an alternative to first-line drug treatment or surgery.

Butterfly Medical’s innovative device is designed to dilate the prostatic urethra without surgical incision or prostate tissue removal. The Butterfly device’s unique design secures tightly to the prostate tissue, preventing any chance of migration, and moves the obstructing lobes of the prostate out of the way to improve urine flow.

https://en.globes.co.il/en/article-butterfly-medical-awarded-ce-mark-for-prostate-device-1001213492